SynBiotic SE (SBX) - Total Assets
Based on the latest financial reports, SynBiotic SE (SBX) holds total assets worth €40.62 Million EUR (≈ $47.49 Million USD) as of December 2022. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SynBiotic SE - Total Assets Trend (2019–2024)
This chart illustrates how SynBiotic SE's total assets have evolved over time, based on quarterly financial data. Also see SBX company net worth for the company's overall valuation and market capitalisation.
SynBiotic SE - Asset Composition Analysis
Current Asset Composition (December 2024)
SynBiotic SE's total assets of €40.62 Million consist of 15.0% current assets and 85.0% non-current assets. Review SynBiotic SE (SBX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.2% |
| Accounts Receivable | €981.48K | 2.2% |
| Inventory | €2.92 Million | 6.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.64 Million | 10.2% |
| Goodwill | €26.61 Million | 58.2% |
Asset Composition Trend (2019–2024)
This chart illustrates how SynBiotic SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SBX stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SynBiotic SE's current assets represent 15.0% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 58.2% of total assets.
SynBiotic SE Competitors by Total Assets
Key competitors of SynBiotic SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
SynBiotic SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 1.46 | 18.53 |
| Quick Ratio | 0.82 | 0.99 | 18.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.31 Million | €3.36 Million | €3.59 Million |
SynBiotic SE - Advanced Valuation Insights
This section examines the relationship between SynBiotic SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 30.9% |
| Total Assets | €45.71 Million |
| Market Capitalization | $7.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values SynBiotic SE's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SynBiotic SE's assets grew by 30.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SynBiotic SE (2019–2024)
The table below shows the annual total assets of SynBiotic SE from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €45.71 Million ≈ $53.44 Million |
+30.91% |
| 2023-12-31 | €34.92 Million ≈ $40.82 Million |
-14.04% |
| 2022-12-31 | €40.62 Million ≈ $47.49 Million |
-33.02% |
| 2021-12-31 | €60.65 Million ≈ $70.90 Million |
+73.14% |
| 2020-12-31 | €35.03 Million ≈ $40.95 Million |
+14602.01% |
| 2019-12-31 | €238.25K ≈ $278.54K |
-- |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more